A new study commissioned by PhRMA finds that many consumers in ObamaCare’s insurance exchanges could end up paying more than twice as much in out-of-pocket drug costs. The report for the nation’s top drug lobby was conducted by actuarial firm Milliman, which found that people on the Silver Plan, the most popular ObamaCare plan, would likely pay 130 percent more for out-of-pocket prescription drugs compared to people on similar employer-sponsored plans. One reason why out-of-pocket costs are likely to be higher is because employer plans are more generous than typical Silver Plans, according to the report. However, the numbers don’t...